| Literature DB >> 33187055 |
Razib Mazumder1, Ahmed Abdullah1, Dilruba Ahmed1, Arif Hussain1.
Abstract
The emergence of multidrug-resistant (MDR) Escherichia coli (E. coli) clonal lineages with high virulence potential is alarming. Lack of sufficient data on molecular epidemiology of such pathogens from countries with high infection burden, such as Bangladesh, hinders management and infection control measures. In this study, we assessed the population structure, virulence potential and antimicrobial susceptibility of clinical E. coli isolates from Dhaka, Bangladesh. A high prevalence of MDR (69%) and extended-spectrum β-lactamase production (ESBL) (51%) was found. Most E. coli isolates were susceptible to amikacin (95%), meropenem (94%) and nitrofurantoin (89%) antibiotics. A high prevalence of ST131 (22%) and ST95 (9%) followed by ST69 (4%) and ST73 (3%) was observed. Phylogroups B2 (46%), B1 (16%), D (10%) and F (9%) were prominent. blaCTX-M-15 (52%) and blaNDM-1 (5%) were the most prevalent ESBL and carbapenem resistance genes, respectively. Moreover, the predominant pathotype identified was extraintestinal pathogenic E. coli (ExPEC) (41%) followed by enteric pathogens (11%). In conclusion, our results suggest the transmission of clonal E. coli groups amidst diverse E. coli population that are associated with high virulence potential and MDR phenotype. This is of high concern and mandates more efforts towards molecular surveillance of antimicrobial resistance (AMR) in clinically significant pathogens.Entities:
Keywords: Bangladesh; Escherichia coli; ST131; blaCTX-M-15; carbapenem resistance; urinary tract infections; virulence genes
Year: 2020 PMID: 33187055 PMCID: PMC7696227 DOI: 10.3390/antibiotics9110796
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
Antimicrobial resistance trends of clinical E. coli isolates to 17 antibiotics from March 2018 to July 2019.
| Antibiotic Class | Antibiotics | No. of Strains Tested | No. of Resistant Strains (%) | No. of Sensitive Strains (%) |
|---|---|---|---|---|
| Aminopenicillin/β lactam | Ampicillin | 128 | 107 (84) | 21 (16) |
| β lactam/β lactamase inhibitor | Amoxiclav | 128 | 70 (55) | 58 (45) |
| Piperacillin-Tazobactam | 128 | 20 (16) | 108 (84) | |
| Aminoglycoside | Gentamicin | 128 | 34 (27) | 94 (73) |
| Amikacin | 128 | 7 (5) | 121 (95) | |
| Sulfonamide | Cotrimoxazole | 128 | 76 (59) | 52 (41) |
| Quinolone/Fluoroquinolone | Nalidixic Acid | 125 | 104 (83) | 21 (17) |
| Ciprofloxacin | 127 | 78 (61) | 49 (39) | |
| Nitrofuran | Nitrofurantoin | 104 | 11 (11) | 93 (89) |
| Cephalosporin | Cefuroxime | 127 | 82 (65) | 45 (35) |
| Ceftriaxone | 125 | 77 (62) | 48 (38) | |
| Ceftazidime | 128 | 66 (52) | 62 (48) | |
| Cefixime | 128 | 85 (66) | 43 (34) | |
| Cefepime | 127 | 59 (46) | 68 (54) | |
| Carbapenem | Imipenem | 128 | 11 (9) | 117 (91) |
| Meropenem | 126 | 8 (6) | 118 (94) |
Molecular characteristics of 128 E. coli isolates analyzed including antimicrobial resistance, virulence and phylogenetic features.
| Characteristics (Overall Positives n, %) | Gene | No. of Positives (%) | |
|---|---|---|---|
| Antibiotic Resistance | ESBL (84, 66%) |
| 66 (52) |
| 66 (52) | |||
| 1 (1) | |||
| 4 (3) | |||
|
| 26 (20) | ||
|
| 22 (17) | ||
| Carbapenem (9, 7%) |
| 6 (5) | |
|
| 1 (1) | ||
|
| 0 | ||
|
| 0 | ||
|
| 2 (2) | ||
| Phylogenetic Groups | A | 6 (5) | |
| B1 | 21 (16) | ||
| B2 | 59 (46) | ||
| C | 9 (7) | ||
| D | 13 (10) | ||
| E | 2 (2) | ||
| F | 11 (9) | ||
| Unknown group | 7 (5) | ||
| Sequence types (48, 37%) | ST-69 | 5 (4) | |
| ST-73 | 4 (3) | ||
| ST-95 | 11 (9) | ||
| ST-131 | 28 (22) | ||
| Pathotypes | ExPEC (52, 41%) |
| 7 (5) |
|
| 31 (24) | ||
|
| 79 (62) | ||
|
| 4 (3) | ||
|
| 75 (59) | ||
|
| 50 (39) | ||
|
| 4 (3) | ||
| EAEC (3, 2%) |
| 1 (1) | |
| CVD432 | 3 (2) | ||
|
| 2 (2) | ||
| ETEC (11, 9%) |
| 10 (8) | |
|
| 2 (2) | ||
| EIEC |
| 0 | |
| EHEC |
| 0 | |
| EPEC |
| 0 | |
| Class 1 integron (27, 21%) |
| 27 (21) | |
| Plasmid-replicon types (70, 55%) | FIA | 70 (55) | |
| FIB | 70 (55) | ||
|
| 11 (9) | ||
|
| 11 (9) | ||
Antibiotic resistance profiles of E. coli isolates harboring carbapenem resistance genes.
| Phylogroup | ESBL Genotype | CR b Genotype | AMR Profile c | No. of Resistant Classes |
|---|---|---|---|---|
| B1 | ND a |
| AMP-COT-NIT-CIP-CXM | 4 |
| C |
|
| AMP-GEN-COT-NAL-NIT-CIP-CRO-CXM-AMX-AMC-TZP | 5 |
| F |
|
| AMP-GEN-COT-NAL-CIP-CRO-CAZ-IPM-CXM-AMX-CFM-AMC-MEM-FEP-TZP | 5 |
| D |
|
| AMP-GEN-COT-NAL-CIP-CRO-CAZ-IPM-CXM-AMX-CFM-AMC-MEM-FEP-TZP | 5 |
| E |
|
| AMP-NAL-NIT-IP-CRO-CAZ-CXM-CFM-AMC-FEP | 3 |
| D |
|
| AMP-GEN-COT-NAL-NIT-CIP-CRO-CAZ-IPM-CXM-AMX-CFM-AMC-MEM-FEP-TZP | 6 |
| ND a |
|
| AMP-CRO-CXM-CFM-FEP | 1 |
| A |
|
| AMP-COT-NAL-CIP-CRO-CAZ-CXM-AMX-CFM-AMC-FEP-TZP | 3 |
| B1 |
|
| AMP-GEN-COT-NAL-NIT-CIP-CRO-CAZ-IMP-CXM-AMK-CFM-AMC-MEM-FEP-TZP | 6 |
a ND, not detected; b Carbapenem resistance genotype; c AMP, ampicillin; GEN, gentamicin; COT, cotrimoxazole; NAl, nalidixic acid; NIT, nitrofurantoin; CIP, ciprofloxacin; CRO, ceftriaxone; CAZ, ceftazidime; IPM, imipenem; CXM, cefuroxime; AMK, amikacin; CFM, cefixime; AMC, amoxicillin-clavulanic acid; MEM, meropenem; FEP, cefepime.